Prognostic benefit of conversion surgery for HER2 positive stage IV gastric cancer; a case series study of eleven patients treated with trastuzumab-based chemotherapy

BACKGROUND: Since the ToGA trial, trastuzumab-based chemotherapy is the standard treatment for HER2 positive stage IV gastric cancer. However, it is not yet clear whether surgical resection after trastuzumab-based chemotherapy (conversion surgery) can improve survival of HER2 positive stage IV gastr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayano, Koichi, Watanabe, Hiroki, Ryuzaki, Takahiro, Sawada, Naoto, Ohira, Gaku, Kano, Masayuki, Uesato, Masaya, Matsubara, Hisahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516002/
https://www.ncbi.nlm.nih.gov/pubmed/32970254
http://dx.doi.org/10.1186/s40792-020-00984-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516002/
https://www.ncbi.nlm.nih.gov/pubmed/32970254
http://dx.doi.org/10.1186/s40792-020-00984-w

Ejemplares similares